NRIX
Nurix Therapeutics, Inc. NASDAQ Listed Jul 24, 2020$16.28
Mkt Cap $1.4B
52w Low $8.20
56.5% of range
52w High $22.50
50d MA $15.92
200d MA $14.18
P/E (TTM)
-5.5x
EV/EBITDA
-5.2x
P/B
2.7x
Debt/Equity
0.1x
ROE
-61.4%
P/FCF
-5.6x
RSI (14)
—
ATR (14)
—
Beta
1.98
50d MA
$15.92
200d MA
$14.18
Avg Volume
1.1M
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
1700 Owens Street · San Francisco, CA 94158 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 8, 2026 | AMC | -0.76 | -0.79 | -3.9% | 15.60 | +0.0% | +4.1% | -1.3% | -0.7% | +2.5% | +4.1% | — |
| Jan 28, 2026 | AMC | -0.84 | -0.82 | +2.4% | 17.87 | +2.1% | -1.6% | -6.1% | +3.5% | -1.8% | -1.4% | — |
| Oct 9, 2025 | AMC | -0.84 | -1.03 | -22.6% | 10.86 | -10.6% | -10.1% | -0.4% | -5.6% | +12.7% | -3.1% | — |
| Jul 9, 2025 | AMC | -0.71 | -0.52 | +26.8% | 13.18 | +9.9% | -3.9% | -1.8% | +2.0% | -4.3% | +2.2% | — |
| Apr 8, 2025 | AMC | -0.72 | -0.67 | +6.9% | 9.26 | -1.0% | +3.7% | -8.2% | +3.7% | +7.8% | -0.3% | — |
| Jan 28, 2025 | AMC | -0.67 | -0.75 | -11.9% | 19.56 | +0.0% | +0.5% | +1.9% | -1.5% | -3.9% | -1.9% | — |
| Oct 11, 2024 | AMC | -0.67 | -0.67 | +0.0% | 23.63 | -0.5% | +6.5% | -1.2% | +3.8% | -4.2% | +1.3% | — |
| Jul 11, 2024 | AMC | -0.66 | -0.71 | -7.6% | 22.03 | -0.8% | +8.1% | -4.8% | +0.6% | -4.6% | -2.8% | — |
| Apr 10, 2024 | AMC | -0.80 | -0.76 | +5.0% | 15.69 | +8.9% | +9.7% | -2.7% | -7.6% | -5.2% | -3.9% | — |
| Feb 15, 2024 | AMC | -0.51 | -0.77 | -51.0% | 9.85 | -6.1% | +0.2% | +2.2% | -0.5% | +5.1% | -3.3% | — |
| Oct 12, 2023 | AMC | -0.69 | -0.68 | +1.4% | 6.23 | +2.6% | +2.2% | +0.6% | -5.1% | -13.2% | -9.8% | — |
| Jul 13, 2023 | AMC | -0.63 | -0.45 | +28.6% | 10.08 | +7.5% | -3.2% | +1.0% | -1.1% | -0.2% | -0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.68 | $16.52 | -1.0% | -1.1% | +3.6% | -2.8% | +0.5% | +0.7% |
| Apr 23 | Needham | Maintains | Buy → Buy | — | $16.63 | $16.69 | +0.4% | -0.4% | +0.7% | -1.1% | +3.6% | -2.8% |
| Apr 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.24 | $16.30 | +0.4% | -1.3% | -0.7% | +2.5% | +4.1% | -1.6% |
| Apr 9 | Wells Fargo | Maintains | Overweight → Overweight | — | $15.60 | $15.60 | +0.0% | +4.1% | -1.3% | -0.7% | +2.5% | +4.1% |
| Apr 8 | Needham | Maintains | Buy → Buy | — | $16.35 | $16.57 | +1.3% | -4.6% | +4.1% | -1.3% | -0.7% | +2.5% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.69 | $14.52 | -1.2% | -1.7% | +6.9% | +0.6% | -5.0% | -0.6% |
| Jan 29 | Wells Fargo | Maintains | Overweight → Overweight | — | $17.87 | $18.25 | +2.1% | -1.6% | -6.1% | +3.5% | -1.8% | -1.4% |
| Jan 29 | BTIG | Maintains | Buy → Buy | — | $17.87 | $18.25 | +2.1% | -1.6% | -6.1% | +3.5% | -1.8% | -1.4% |
| Jan 29 | Stifel | Maintains | Buy → Buy | — | $17.87 | $18.25 | +2.1% | -1.6% | -6.1% | +3.5% | -1.8% | -1.4% |
| Jan 29 | Needham | Maintains | Buy → Buy | — | $17.87 | $18.25 | +2.1% | -1.6% | -6.1% | +3.5% | -1.8% | -1.4% |
| Jan 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.87 | $18.25 | +2.1% | -1.6% | -6.1% | +3.5% | -1.8% | -1.4% |
| Jan 29 | RBC Capital | Maintains | Outperform → Outperform | — | $17.87 | $18.25 | +2.1% | -1.6% | -6.1% | +3.5% | -1.8% | -1.4% |
| Jan 29 | Piper Sandler | Maintains | Overweight → Overweight | — | $17.87 | $18.25 | +2.1% | -1.6% | -6.1% | +3.5% | -1.8% | -1.4% |
| Jan 8 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $18.49 | $19.86 | +7.4% | +0.8% | +3.6% | -4.8% | +3.0% | +0.6% |
| Dec 16 | Wells Fargo | Maintains | Overweight → Overweight | — | $19.01 | $19.06 | +0.3% | -0.9% | -3.3% | -1.1% | +2.8% | +4.4% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.55 | $20.07 | +2.7% | +0.3% | -2.8% | +0.0% | -0.3% | -0.9% |
| Dec 10 | Mizuho | Maintains | Outperform → Outperform | — | $19.55 | $20.07 | +2.7% | +0.3% | -2.8% | +0.0% | -0.3% | -0.9% |
| Dec 9 | BTIG | Maintains | Buy → Buy | — | $21.47 | $21.43 | -0.2% | -8.9% | +0.3% | -2.8% | +0.0% | -0.3% |
| Dec 8 | Needham | Maintains | Buy → Buy | — | $18.09 | $21.43 | +18.5% | +18.7% | -8.9% | +0.3% | -2.8% | +0.0% |
| Nov 4 | BTIG | Maintains | Buy → Buy | — | $12.62 | $12.30 | -2.5% | -2.9% | +1.6% | +0.5% | -1.7% | -0.5% |
| Nov 4 | Needham | Maintains | Buy → Buy | — | $12.62 | $12.30 | -2.5% | -2.9% | +1.6% | +0.5% | -1.7% | -0.5% |
| Oct 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.09 | $11.21 | +1.1% | +8.0% | -0.7% | -1.7% | +9.2% | +1.3% |
| Oct 23 | Wells Fargo | Maintains | Overweight → Overweight | — | $10.63 | $10.54 | -0.8% | -2.2% | +6.6% | +8.0% | -0.7% | -1.7% |
| Oct 23 | BTIG | Maintains | Buy → Buy | — | $10.63 | $10.54 | -0.8% | -2.2% | +6.6% | +8.0% | -0.7% | -1.7% |
| Oct 22 | Needham | Maintains | Buy → Buy | — | $10.42 | $11.69 | +12.2% | +2.0% | -2.2% | +6.6% | +8.0% | -0.7% |
| Oct 20 | Needham | Maintains | Buy → Buy | — | $9.84 | $10.09 | +2.5% | +5.6% | +0.3% | +2.0% | -2.2% | +6.6% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.84 | $10.09 | +2.5% | +5.6% | +0.3% | +2.0% | -2.2% | +6.6% |
| Oct 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.72 | $9.43 | -3.0% | -5.6% | +12.7% | -3.1% | -1.9% | +5.6% |
| Oct 14 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $9.72 | $9.43 | -3.0% | -5.6% | +12.7% | -3.1% | -1.9% | +5.6% |
| Oct 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $10.86 | $9.71 | -10.6% | -10.1% | -0.4% | -5.6% | +12.7% | -3.1% |
| Oct 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.86 | $9.71 | -10.6% | -10.1% | -0.4% | -5.6% | +12.7% | -3.1% |
| Jul 31 | Oppenheimer | Maintains | Outperform → Outperform | — | $11.88 | $11.55 | -2.8% | -5.2% | -2.0% | +2.2% | +0.3% | -7.5% |
| Jul 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $12.69 | $12.68 | -0.1% | -4.3% | +2.2% | -2.7% | -7.3% | +0.4% |
| Jul 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.44 | $12.25 | -1.5% | +2.0% | -4.3% | +2.2% | -2.7% | -7.3% |
| Jul 10 | UBS | Maintains | Buy → Buy | — | $13.18 | $14.48 | +9.9% | -3.9% | -1.8% | +2.0% | -4.3% | +2.2% |
| Jul 10 | Stephens & Co. | Maintains | Overweight → Overweight | — | $13.18 | $14.48 | +9.9% | -3.9% | -1.8% | +2.0% | -4.3% | +2.2% |
| Jul 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $13.18 | $14.48 | +9.9% | -3.9% | -1.8% | +2.0% | -4.3% | +2.2% |
| Apr 29 | Needham | Maintains | Buy → Buy | — | $11.47 | $11.54 | +0.6% | -0.3% | +0.8% | -3.2% | +1.0% | -2.9% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $9.26 | $9.17 | -1.0% | +3.7% | -8.2% | +3.7% | +7.8% | -0.3% |
| Apr 9 | Wells Fargo | Maintains | Overweight → Overweight | — | $9.26 | $9.17 | -1.0% | +3.7% | -8.2% | +3.7% | +7.8% | -0.3% |
| Apr 9 | Stifel | Maintains | Buy → Buy | — | $9.26 | $9.17 | -1.0% | +3.7% | -8.2% | +3.7% | +7.8% | -0.3% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.47 | $10.30 | -1.6% | +8.7% | -7.6% | -7.8% | +0.3% | -4.7% |
| Feb 3 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $19.71 | $19.60 | -0.6% | -3.9% | -1.9% | +3.3% | -0.8% | -0.8% |
| Jan 29 | Needham | Maintains | Buy → Buy | — | $19.56 | $19.56 | +0.0% | +0.5% | +1.9% | -1.5% | -3.9% | -1.9% |
| Jan 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.56 | $19.56 | +0.0% | +0.5% | +1.9% | -1.5% | -3.9% | -1.9% |
| Jan 29 | RBC Capital | Maintains | Outperform → Outperform | — | $19.56 | $19.56 | +0.0% | +0.5% | +1.9% | -1.5% | -3.9% | -1.9% |
| Jan 29 | Stifel | Maintains | Buy → Buy | — | $19.56 | $19.56 | +0.0% | +0.5% | +1.9% | -1.5% | -3.9% | -1.9% |
| Jan 29 | JP Morgan | Maintains | Overweight → Overweight | — | $19.56 | $19.56 | +0.0% | +0.5% | +1.9% | -1.5% | -3.9% | -1.9% |
| Jan 21 | Stephens & Co. | Maintains | Overweight → Overweight | — | $19.14 | $19.42 | +1.5% | +2.4% | +0.4% | +1.4% | -0.2% | -0.6% |
| Dec 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.06 | $22.95 | +4.0% | -3.4% | -3.5% | -1.4% | +2.7% | +1.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | van Houte HansOff | Chief Financial Officer | Sell | 582 | $17.18 | $10K | 37,592 | +1.69% | — |
| May 5, 2026 | van Houte HansOff | Chief Financial Officer | Sell | 13,473 | $16.58 | $223K | 38,174 | +1.69% | — |
| May 4, 2026 | Ring ChristineOff | Chief Legal Officer | Sell | 8,148 | $16.96 | $138K | 18,305 | -1.95% | — |
| May 1, 2026 | Ring ChristineOff | Chief Legal Officer | Sell | 5,394 | $16.76 | $90K | 26,453 | +0.71% | +1.47% |
| Apr 30, 2026 | Ring ChristineOff | Chief Legal Officer | Sell | 3,214 | $16.65 | $53K | 31,847 | +0.66% | -3.55% |
| Apr 30, 2026 | van Houte HansOff | Chief Financial Officer | Sell | 2,388 | $16.65 | $40K | 51,647 | +0.66% | -3.55% |
| Apr 30, 2026 | Hansen GwennOff | Chief Scientific Officer | Sell | 3,214 | $16.65 | $53K | 120,399 | +0.66% | -3.55% |
8-K
Unknown — 8-K Filing
Nurix's advancement toward regulatory approval of bexobrutideg and multiple 2026 catalysts could significantly de-risk the company and drive stock appreciation if clinical milestones succeed.
Apr 8
8-K
Nurix Therapeutics, Inc. -- 8-K Filing
Nurix Therapeutics received legal counsel confirmation that its share offering complies with securities registration requirements across jurisdictions.
Mar 6
Data updated apr 26, 2026 3:44pm
· Source: massive.com